References
- dos Santos JL , LanaroC, ChinCM. Advances in sickle cell disease treatment: from drug discovery until the patient monitoring. Cardiovasc. Hematol. Agents Med. Chem.9 (2), 113–127 (2011).
- Derebail VK , NachmanPH, KeyNS, AnsedeH, FalkRJ, KshirsagarAV. High Prevalence of sickle cell trait in African Americans with ESRD. J. Am. Soc. Nephrol.21 (3), 413–417 (2010).
- Manwani D , FrenettePS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood122 (24), 3892–3898 (2013).
- Rees DC , WilliamsTN, GladwinMT. Sickle-cell disease. Lancet376 (9757), 2018–2031 (2010).
- Herrick JB . Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910. Yale J. Biol. Med.74 (3), 179–184 (2001).
- Powars DR , WeissJN, ChanLS, SchroederWA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?Blood63 (4), 921–926 (1984).
- dos Santos JL , ChinCM. Recent insights on the medicinal chemistry of sickle cell disease. Curr. Med. Chem.18 (15), 2339–2358 (2011).
- Ataga KI , ReidM, BallasSK; ICA-17043-17010 Study Investigatorset al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a Phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br. J. Haematol.153 (1), 92–104 (2011).
- Saunthararajah Y , MolokieR, SarafSet al. Clinical effectiveness of decitabine in severe sickle cell disease. Br. J. Haematol.141 (1), 126–129 (2008).
- Resar LM , SegalJB, FitzpatricLK, FriedmannA, BrusilowSW, DoverGJ. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J. Pediat. Hematol. Oncol.24 (9), 737–741 (2002).
- Kutlar A , ReidME, InatiAet al. A dose-escalation Phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am. J. Hematol.88 (11), 255–260 (2013).
- Aerbajinai W , ZhuJ, GaoZ, ChinK, RodgersGP. Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood110 (8), 2864–2871 (2007).
- Moutouh-de-Parseval LA , VerhelleD, GlezerEet al. Pomalidomide and lenalidomide regulate erythopoiesis and fetal hemoglobin production in human CD34+ cells. J. Clin. Invest.118 (1), 248–258 (2008).
- Vandy Black L , SmithWR. Evidence-based mini-review: are systemic corticosteroids an effective treatment for acute pain in sickle cell disease?Hematology Am. Soc. Hematol. Educ. Program.416 − 417 (2010).
- Dos Santos JL , LanaroC, LimaLMet al. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. J. Med. Chem.54 (16), 5811–5819 (2011).
- Dos Santos JL , LanaroC, ChelucciRCet al. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. Part II: furoxan derivatives. J. Med. Chem.55 (17), 7583–7592 (2012).
- Essack M , RadovanovicA, BajicVB. Information exploration system for sickle cell disease and repurposing of hydroxyfasudil. PLoS ONE8 (6), e65190 (2013).
- Field JJ , LinG, OkamMMet al. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood121 (17), 3329–3334 (2013).